REGENERON PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 937.6 USD | +3.78% |
|
+5.27% | +6.75% |
| 08:52pm | Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,183 From $1,177 | MT |
| 07:55pm | Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,000.25 From $1,016 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Calendar
04:00pm
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
903.5
USD
Average target price
1,038
USD
Spread / Average Target
+14.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.75% | 97.47B | |
| -1.65% | 104B | |
| +5.71% | 22.25B | |
| -12.60% | 21.68B | |
| -9.70% | 18.2B | |
| -39.98% | 17.02B | |
| -10.17% | 16.36B | |
| +6.12% | 14.39B | |
| +35.47% | 12.37B | |
| +307.09% | 8.43B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Japan Grants Marketing, Manufacturing Authorization for Regeneron Pharmaceuticals' Libtayo to Treat Cervical Cancer
